Peiying Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peiying Huang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Lining Huang
Department of Anesthesiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
2 shared publications - Aiyan Zhang
Department of Pneumology The Second Hospital of Hebei Medical University Shijiazhuang 050000 China hebmu.edu.cn
1 shared publication Huan Chen
Hebei Key Laboratory of Neurodegenerative Disease Mechanism Hebei Medical University Shijiazhuang Hebei China
1 shared publicationLichao Di
Department of Anesthesiology The Second Hospital of Hebei Medical University Shijiazhuang Hebei China
1 shared publicationLonglu Cao
Department of Anesthesiology The Second Hospital of Hebei Medical University Shijiazhuang Hebei China
1 shared publication- Sha Li
Department of Human Anatomy, Neuroscience Research Center, Hebei Medical University, Shijiazhuang, China
1 shared publication
Latest Publications
- Open Access
- 22 January 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (1) , e70748
Intermittent Fasting Alleviates Anesthesia/Surgery‐Induced Delirium‐Like Behavior in Aged Mice by Remodeling Gut Microbiota
Background: Postoperative delirium (POD) is a serious complication in elderly patients, associated with prolonged recovery and adverse outcomes. Recent evidence links POD to mitochondrial dysfunction. While intermittent fasting (IF) has been shown to enhance mitochondrial function and exert neuroprotective effects, potentially through gut microbiota modulation, its ability to prevent POD and the underlying mechanisms remain unclear. Methods: We examined the effects of preoperative IF on delirium‐like behavior in aged mice following anesthesia/surgery. Assessments included neurobehavioral tests, gut microbiota composition, fecal shortchain fatty acids (SCFAs), hippocampal synaptic and mitochondrial ultrastructure via transmission electron microscopy, mitochondrial function, and related molecular markers. To establish causality, fecal microbiota transplantation and SCFA supplementation experiments were conducted. Results: Preoperative IF significantly attenuated anesthesia/surgery‐induced delirium‐like behaviors. Mechanistically, IF reshaped the gut microbiota and preserved SCFA levels, which collectively maintained hippocampal mitochondrial homeostasis. Both fecal microbiota transplantation and SCFA supplementation replicated the protective effects of IF, confirming the causal role of gut microbiota and its metabolites. Conclusion: These findings demonstrate that preoperative intermittent fasting mitigates delirium‐like behavior by modulating the gut microbiota–SCFA–mitochondrial axis, highlighting its potential as a non‐pharmacological strategy to enhance neurocognitive resilience and prevent POD in elderly surgical patients.
- 22 January 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (1) , e70748
Open AccessIntermittent Fasting Alleviates Anesthesia/Surgery‐Induced Delirium‐Like Behavior in Aged Mice by Remodeling Gut Microbiota
Background: Postoperative delirium (POD) is a serious complication in elderly patients, associated with prolonged recovery and adverse outcomes. Recent evidence links POD to mitochondrial dysfunction. While intermittent fasting (IF) has been shown to enhance mitochondrial function and exert neuroprotective effects, potentially through gut microbiota modulation, its ability to prevent POD and the underlying mechanisms remain unclear. Methods: We examined the effects of preoperative IF on delirium‐like behavior in aged mice following anesthesia/surgery. Assessments included neurobehavioral tests, gut microbiota composition, fecal shortchain fatty acids (SCFAs), hippocampal synaptic and mitochondrial ultrastructure via transmission electron microscopy, mitochondrial function, and related molecular markers. To establish causality, fecal microbiota transplantation and SCFA supplementation experiments were conducted. Results: Preoperative IF significantly attenuated anesthesia/surgery‐induced delirium‐like behaviors. Mechanistically, IF reshaped the gut microbiota and preserved SCFA levels, which collectively maintained hippocampal mitochondrial homeostasis. Both fecal microbiota transplantation and SCFA supplementation replicated the protective effects of IF, confirming the causal role of gut microbiota and its metabolites. Conclusion: These findings demonstrate that preoperative intermittent fasting mitigates delirium‐like behavior by modulating the gut microbiota–SCFA–mitochondrial axis, highlighting its potential as a non‐pharmacological strategy to enhance neurocognitive resilience and prevent POD in elderly surgical patients.
- Open Access
- 11 December 2023
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2023, 1-8
Esketamine Combined with Propofol TCI versus Propofol TCI for Deep Sedation during Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: A Prospective, Randomized, and Controlled Trial
Background. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is an invasive procedure that required deep sedation to suppress coughing and body movements. Deep sedation, on the other hand, has been shown to cause respiratory and circulatory depression, especially when the airway is shared with the endoscopist. Esketamine is a novel sedative and analgesic with little respiratory inhibition that appears to be an appropriate adjuvant in propofol sedation for EBUS-TBNA. We compared the efficacy and safety of esketamine combined with propofol target-controlled infusion (TCI) and propofol TCI for deep sedation in EBUS-TBNA. Methods. The study included 135 patients with ASA II-III undergoing EBUS-TBNA. They were randomly divided into two groups (group E and group P). Both groups received midazolam (0.01–0.03 mg/kg) and oxycodone (0.07–0.08 mg/kg). Then, patients in group E received 0.3 mg/kg esketamine, propofol TCI, and 0.2 mg·kg−1·h−1 esketamine for sedative maintenance. Patients in group P received only propofol TCI. The primary outcome was the dose of 1% lidocaine administrated by the endoscopist and the times of lidocaine sprays. Secondary outcome indicators were cough score, propofol dosage, patient satisfaction, endoscopist satisfaction, the incidence of sedation-related adverse effects and side effects, and recovery time. Results. Patients in group E were given significantly less lidocaine (4.36 ml/h (2.67–6.00) vs 6.00 ml/h (4.36–7.20), ) and less spraying frequency (2.18 times/h (1.33–3.00) vs 3.00 times/h (2.18–3.60), ) than group P. There was a statistically significant difference in cough score between the two groups (group E 2 (0–4) vs group P 3 (2–4), ). Also, mean arterial pressure (MAP) was higher in group E in the 30th min (T5, 84.10 ± 12.91 mmHg versus 79.04 ± 10.01 mmHg, ) and 40th min (T6, 87.72 ± 15.55 mmHg versus 82.14 ± 10.51 mmHg, ). There were no significant differences between the two groups in terms of sedation-related adverse events and side effects, recovery time, endoscopist satisfaction, and patient satisfaction. Conclusions. In patients with ASA II-III, esketamine as an adjuvant in combination with propofol TCI deep sedation for EBUS-TBNA can improve the sedation effect, reduce coughing reaction during the procedure, and obtain more stable blood pressure. No reduction in the occurrence of sedation-related side effects was observed. This trial is registered with ChiCTR2200061124.
- 11 December 2023
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2023, 1-8
Open AccessEsketamine Combined with Propofol TCI versus Propofol TCI for Deep Sedation during Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: A Prospective, Randomized, and Controlled Trial
Background. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is an invasive procedure that required deep sedation to suppress coughing and body movements. Deep sedation, on the other hand, has been shown to cause respiratory and circulatory depression, especially when the airway is shared with the endoscopist. Esketamine is a novel sedative and analgesic with little respiratory inhibition that appears to be an appropriate adjuvant in propofol sedation for EBUS-TBNA. We compared the efficacy and safety of esketamine combined with propofol target-controlled infusion (TCI) and propofol TCI for deep sedation in EBUS-TBNA. Methods. The study included 135 patients with ASA II-III undergoing EBUS-TBNA. They were randomly divided into two groups (group E and group P). Both groups received midazolam (0.01–0.03 mg/kg) and oxycodone (0.07–0.08 mg/kg). Then, patients in group E received 0.3 mg/kg esketamine, propofol TCI, and 0.2 mg·kg−1·h−1 esketamine for sedative maintenance. Patients in group P received only propofol TCI. The primary outcome was the dose of 1% lidocaine administrated by the endoscopist and the times of lidocaine sprays. Secondary outcome indicators were cough score, propofol dosage, patient satisfaction, endoscopist satisfaction, the incidence of sedation-related adverse effects and side effects, and recovery time. Results. Patients in group E were given significantly less lidocaine (4.36 ml/h (2.67–6.00) vs 6.00 ml/h (4.36–7.20), ) and less spraying frequency (2.18 times/h (1.33–3.00) vs 3.00 times/h (2.18–3.60), ) than group P. There was a statistically significant difference in cough score between the two groups (group E 2 (0–4) vs group P 3 (2–4), ). Also, mean arterial pressure (MAP) was higher in group E in the 30th min (T5, 84.10 ± 12.91 mmHg versus 79.04 ± 10.01 mmHg, ) and 40th min (T6, 87.72 ± 15.55 mmHg versus 82.14 ± 10.51 mmHg, ). There were no significant differences between the two groups in terms of sedation-related adverse events and side effects, recovery time, endoscopist satisfaction, and patient satisfaction. Conclusions. In patients with ASA II-III, esketamine as an adjuvant in combination with propofol TCI deep sedation for EBUS-TBNA can improve the sedation effect, reduce coughing reaction during the procedure, and obtain more stable blood pressure. No reduction in the occurrence of sedation-related side effects was observed. This trial is registered with ChiCTR2200061124.